Skip to main content
. 2024 Feb 16;25(4):2345. doi: 10.3390/ijms25042345

Figure 8.

Figure 8

Swimmer plot illustrating the individual clinical course of the 6 patients who either received the biomarker-guided targeted therapy recommended by the MTB (mTOR inhibitor temsirolimus) or a biomarker-agnostic targeted therapy (i.e., an antibody–drug conjugate or a checkpoint inhibitor). Patient identifiers refer to Table S1.